Search Results

FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced Boyd Clarke, Executive Chairman is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference.

FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, announced management is scheduled to present at the Baird 2021 Global Healthcare Conference on Tuesday, September 14 at 5:30 PM E.T.

FluGen, Inc. today announced the publication of new data in the Journal of Infectious Diseases showing its investigational, high dose, intranasal H3N2 M2SR influenza vaccine candidate substantially enhanced mucosal and serum antibodies against drifted H3N2 influenza viruses.

FluGen, Inc., today announced the completion of enrollment of the first cohort in an age de-escalation clinical trial of M2SR (M2 Deficient Single Replication) live virus vaccine, the company’s investigational supra-seasonal intranasal influenza (flu) vaccine, in volunteers ages 6 months to 17 years old.

An international collaboration of virologists at the University of Wisconsin–Madison and the vaccine companies FluGen and Bharat Biotech has begun the development and testing of a unique vaccine against COVID-19 called CoroFlu.

FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, announced the publication of results from its Phase 2 human challenge study of Bris2007 M2SR, the Company’s investigational, supra-seasonal, live, single-replication, intranasal influenza vaccine.

FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, announced that it has been awarded funding from the United States Department of Defense to conduct a safety and immunogenicity study of M2SR, the Company’s investigational, supra-seasonal, live, single-replication, intranasal influenza vaccine.